IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC.
Wirth L, Burtness B, Mehra R, Bauman J, Lee J, Smith N, Lefranc-Torres A, Westra W, Bishop J, Faquin W, Lin D, Pai S. IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC. Journal Of Clinical Oncology 2017, 35: 6053-6053. DOI: 10.1200/jco.2017.35.15_suppl.6053.Peer-Reviewed Original ResearchHPV- HNSCCsPD-L1Clinical responseHNSCC patientsResponse rateAnti-PD-1 monotherapyAnti-PD-1 therapyHuman papillomavirus-associated headAnti-PD-1 blockadeNeck squamous cell carcinomaAdaptive immune resistanceAnti-PD1 monotherapyHPV(-) HNSCC patientsImmunogenic viral antigensImmune checkpoint moleculesPost-treatment biopsiesT cell activityImmune checkpoint pathwaysSquamous cell carcinomaQuantitative PCRImproved response ratesImmune-related genesCheckpoint moleculesPD-1IDO1 expression